Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2008 1
2009 3
2010 3
2011 1
2012 3
2013 4
2014 5
2015 2
2016 2
2017 6
2018 4
2019 6
2020 4
2021 1
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
Terenziani R, Zoppi S, Fumarola C, Alfieri R, Bonelli M. Terenziani R, et al. Among authors: fumarola c. Cancers (Basel). 2021 Jun 4;13(11):2793. doi: 10.3390/cancers13112793. Cancers (Basel). 2021. PMID: 34199722 Free PMC article. Review.
New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA, Fumarola C, La Monica S, Alfieri R. Bonelli MA, et al. Among authors: fumarola c. Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16. Biochem Pharmacol. 2017. PMID: 27431778 Review.
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Galvani E, et al. Among authors: fumarola c. Curr Pharm Des. 2013;19(5):818-32. Curr Pharm Des. 2013. PMID: 22973953 Review.
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. Digiacomo G, et al. Among authors: fumarola c. Front Oncol. 2022 Jul 22;12:942341. doi: 10.3389/fonc.2022.942341. eCollection 2022. Front Oncol. 2022. PMID: 35936714 Free PMC article.
51 results